<SEC-DOCUMENT>0000950170-24-006150.txt : 20240122
<SEC-HEADER>0000950170-24-006150.hdr.sgml : 20240122
<ACCEPTANCE-DATETIME>20240122172424
ACCESSION NUMBER:		0000950170-24-006150
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240122
DATE AS OF CHANGE:		20240122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Surrozen, Inc./DE
		CENTRAL INDEX KEY:			0001824893
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				301374889
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-259496
		FILM NUMBER:		24549880

	BUSINESS ADDRESS:	
		STREET 1:		171 OYSTER POINT BLVD
		STREET 2:		SUITE 400
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-475-2820

	MAIL ADDRESS:	
		STREET 1:		171 OYSTER POINT BLVD
		STREET 2:		SUITE 400
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Consonance-HFW Acquisition Corp.
		DATE OF NAME CHANGE:	20200915
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>srzn_424b3_20240122.htm
<DESCRIPTION>424B3
<TEXT>
<html>
 <head>
  <title>424B3</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.34%;"></td>
    <td style="width:45.66%;"></td>
   </tr>
   <tr style="height:9.35pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PROSPECTUS SUPPLEMENT NO.7</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Filed Pursuant to Rule 424(b)(3)</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:9.35pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(To the Prospectus dated April 7, 2023)</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Registration No. 333-259496</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img105294373_0.jpg" alt="img105294373_0.jpg" style="width:251px;height:79px;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Up to 1,972,157 Shares of Common Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Including up to 471,539 Shares of Common Stock Issuable Upon Exercise of Warrants)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Up to 4,066,657 Warrants to Purchase Common Stock</font></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">This prospectus supplement updates and supplements the prospectus dated April 7, 2023 (as amended, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), which forms a part of our Registration Statement on Form S-1 (No. 333-259496). This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 18, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Report</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Accordingly, we have attached the Report to this prospectus supplement.</font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Prospectus and this prospectus supplement relate to the issuance by us of an aggregate of up to 471,539 shares of our common stock, $0.0001 par value per share (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), which consists of:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">up to 267,096 shares of Common Stock that are issuable upon the exercise of 4,006,657 warrants (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">PIPE Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) originally issued connection with a private placement immediately prior to the consummation of the Business Combination, and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">up to 204,443 shares of Common Stock that are issuable upon the exercise of 3,066,651 warrants (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Public Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and, together with the PIPE Warrants, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) originally issued in the initial public offering of Consonance.</font></div></div>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Prospectus and this prospectus supplement also relate to the offer and sale from time to time by the selling securityholders named in the Prospectus or their permitted transferees (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Selling Securityholders</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">up to 1,972,157 shares of Common Stock consisting of:</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.637062819289283%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">up to 801,327 shares of Common Stock issued in a private placement pursuant to subscription agreements (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Subscription Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) entered into on April 15, 2021,</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.637062819289283%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">up to 6,000 shares of Common Stock transferred by Consonance Life Sciences to the independent directors of Consonance-HFW Acquisition Corp.,</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.637062819289283%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">up to 267,096 shares of Common Stock issuable upon exercise of the PIPE Warrants,</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.637062819289283%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">up to 89,996 shares of Common Stock issuable upon the exercise of stock options, and</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.637062819289283%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">up to 807,738 shares of Common Stock and Common Stock issuable upon exercise of Warrants issued to certain former securityholders of Surrozen Operating, Inc. pursuant to the Business Combination Agreement entered into on April 15, 2021.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">up to 4,006,657 PIPE Warrants.</font></div></div>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As a result of the 1-for-15 reverse stock split effected on December 13, 2023, each Warrant is exercisable for 1/15th of a share of Common Stock. As no fractional shares will be issued upon an exercise of a Warrant, holders must exercise 15 Warrants to receive one whole share of Common Stock.</font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Selling Securityholders may offer, sell or distribute all or a portion of the registered securities publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any of the proceeds from such sales of the shares of Common Stock or Warrants, except with respect to amounts received by us upon exercise of the Warrants. We will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or &#x201c;blue sky&#x201d; laws. The selling securityholders will bear all commissions and discounts, if any, attributable to their sale of shares of Common Stock or Warrants. See the section titled &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan of Distribution</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; in the Prospectus.</font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The Common Stock and Public Warrants are listed on The Nasdaq Capital Market (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) under the symbols &#x201c;SRZN&#x201d; and &#x201c;SRZNW&#x201d; respectively. On January 19, 2024, the last reported sales price of our Common Stock was $8.02 per share and the last reported sales price of our Public Warrants was $0.0194 per Public Warrant.</font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">This prospectus supplement should be read in conjunction with the Prospectus, including any other amendments or supplements thereto, which is to be delivered with this prospectus supplement. This prospectus supplement is qualified by reference to the Prospectus, including any other amendments or supplements thereto, except to the extent that the information in this prospectus supplement updates and supersedes the information contained therein.</font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any other amendments or supplements thereto.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; and a &#x201c;smaller reporting company&#x201d; as defined under U.S. federal securities laws and, as such, have elected to comply with reduced public company reporting requirements. The Prospectus and this prospectus supplement comply with the requirements that apply to an issuer that is an emerging growth company and a smaller reporting company. We are incorporated in Delaware.</font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;Risk Factors&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">beginning on page 10 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.</font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Prospectus supplement dated January 22, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #808080;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM 8-K</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): January 18, 2024</font></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Surrozen, Inc.</font></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"></td>
    <td style="width:1%;"></td>
    <td style="width:20%;"></td>
    <td style="width:18%;"></td>
    <td style="width:41%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39635</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">30-1374889</font></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br>of Incorporation)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br>Identification No.)</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">171 Oyster Point Blvd</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 400</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">South San Francisco, California</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">94080</font></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">+1</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(650)</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">489-9000</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:24.45pt;text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><font style="margin-right:1em;"><font style="font-size:10pt;font-family:Times New Roman;">&#9744;</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>
  <div style="margin-left:24.45pt;text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><font style="margin-right:1em;"><font style="font-size:10pt;font-family:Times New Roman;">&#9744;</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
  <div style="margin-left:24.45pt;text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><font style="margin-right:1em;"><font style="font-size:10pt;font-family:Times New Roman;">&#9744;</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
  <div style="margin-left:24.45pt;text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><font style="margin-right:1em;"><font style="font-size:10pt;font-family:Times New Roman;">&#9744;</font></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"></td>
    <td style="width:1%;"></td>
    <td style="width:15%;"></td>
    <td style="width:1%;"></td>
    <td style="width:45%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br>Title of each class</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br>Symbol(s)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br>Name of each exchange on which registered</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.0001 par value per share</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">SRZN</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Capital Market</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redeemable warrants, each whole warrant exercisable for one share of Common Stock</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">SRZNW</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Capital Market</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </font><font style="font-size:10pt;font-family:Times New Roman;">&#9746;</font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-size:10pt;font-family:Times New Roman;">&#9744;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01. Other Events.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">         On January 18, 2024, Surrozen, Inc. issued a press release providing a business update regarding our research and development pipeline updates.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">         The enrollment for the SZN-043 Phase 1a clinical trial in patients with chronic liver disease and healthy volunteers is complete. Surrozen expects to release safety and pharmacodynamic data in Q1 2024. In addition, Surrozen anticipates initiating enrollment in the Phase 1b portion of the study in patients with alcohol-associated hepatitis soon with proof-of-concept data from the study potentially available in the second half of 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">         Following the completion of the Phase 1 single ascending dose clinical trial for SZN-1326, Surrozen will discontinue development of SZN-1326 in inflammatory bowel disease (IBD). The decision was based on the challenges of identifying a safe and potentially effective dose along with strategic considerations including the significant clinical development expenses and market competition in IBD. SZN-1326 has been evaluated in a Phase 1 single ascending dose clinical trial in 37 healthy volunteers in doses ranging from 0.01mg to 25mg. Several subjects at higher dose levels experienced asymptomatic liver transaminase elevations, including four subjects with grade 3 ALT and AST elevations. Surrozen previously reported that 3 of these 4 subjects had grade 3 ALT and AST elevations in 2022. No other clinically significant laboratory abnormalities were observed, and the transaminase elevations resolved spontaneously in all subjects. No serious adverse events were observed during the study. While no safety signal was observed at lower doses, lower dose levels would not be expected to activate Wnt signaling and produce a pharmacologic effect in the intestine.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forward Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">         This current report contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as &#x201c;will,&#x201d; &#x201c;plan,&#x201d; &#x201c;intend,&#x201d; &#x201c;potential,&#x201d; &#x201c;expect,&#x201d; &#x201c;could,&#x201d; or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen&#x2019;s discovery, research and development activities, in particular its development plans for its product candidates SZN-043, and SZN-413 (including anticipated clinical development timelines and the availability of data, the potential for such product candidates to be used to treat human disease), the potential and timeline to nominate the lead development candidate pursuant to its partnership with Boehringer Ingelheim and its expectations with respect to its cash runway.  These statements are based on various assumptions, whether or not identified in this current report, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical or and clinical trials with respect to SZN-043, SZN-413 and potential future drug candidates; the Company&#x2019;s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen&#x2019;s ability to identify, develop and commercialize drug candidates; Surrozen&#x2019;s ability to successfully complete preclinical and clinical studies for SZN-043, SZN-413, or other future product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022 and Surrozen&#x2019;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 under the heading &#x201c;Risk Factors,&#x201d; and other documents Surrozen has filed, or will file, with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen&#x2019;s expectations, plans, or forecasts of future events and views as of the date of this current report. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen&#x2019;s assessments of any date after the date of this current report. Accordingly, undue reliance should not be placed upon the forward-looking statements. <br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">         Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;"></td>
    <td style="width:42%;"></td>
    <td style="width:6%;"></td>
    <td style="width:46%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SURROZEN, INC.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 18, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Charles Williams</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: Charles Williams<br>Title: Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img105294373_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img105294373_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !/ /L# 2(  A$! Q$!_\0
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MS(Y'&Z! ^ .X+Y)]!7@.C?$+QAXST^34?%/BK6/$$]RQ*0WM\\D2+G@+&3@
MGT]J]G"Y74Q$ESOE1Y..QT<+3<DKO9>I^B>C?M):E\3O&$N@> ?#OVNSC?%S
MX@OG9;>%>S; O.>P+ FO=M&M[VST^&/4+I;Z[4?O+E8Q$&/^Z,X_7ZU\2_M
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MS<E%8#)"K^5>L_L9V[3?M4?M4:A&=]J?$-M;!P>#(HF+#\,UY#^V%:ZS>?\
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M&O,IX)XC&RLO=3N_S.[$XR.'H:OWGHBG^PKX!D\5_M!Z+=-%OLM AEU*=VR
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-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
